India Equity Research | Power January 29, 2023 **Result Update**

NTPC

Refer to important disclosures at the end of this report

Who has the capacity now?

Result highlights

- NTPC reported adjusted PAT of Rs44.2bn 18% YoY growth in 3Q, taking 9MFY23 growth to ~10% YoY. PAT was above consensus/our estimates, with under-recovery coming down and 3Q turning out to be a decent guarter from the incentive perspective.
- PAF for coal units stood at 92.67% in 3QFY23 vs 85.98%. Coal PLF for 9MFY23 stands at 74.45% vs 69.1% YoY. Utilization of NTPC units have been on the rise since the last few years, on strong power demand in the country. We believe that given the high operational standard of NTPC units, PLFs can go above 90% in coming years, if demand growth continues.
- We maintain BUY with Mar-24 TP of Rs200. We raise our EPS estimates by ~4% each for FY23/FY24/FY25. High utilization, strong capacity addition and RE monetization are all positives for the company, in our view.
- FY23 PAT growth to be ~10% YoY: We estimated 10% EPS growth for FY23 on the back of capacity addition, lower under-recovery and higher incentives. 9MFY23 PAT growth stands at ~10% YoY, despite the lower PAT for JVs/subsidiaries, which can see recovery in FY24. Our FY24E EPS growth also stands at 10%, indicating a strong earnings trajectory. Over the last one year (since Dec-21), NTPC/NTPC Group have added 2.2GW/3.1GW capacity, respectively.
- Who has the capacity now?: Power demand in India has been on the upswing and, given the demand-supply dynamics, PLF of existing units is expected to rise from current levels. At the end of 9MFY23, NTPC-coal/All-India thermal units clocked ~75%/~63% PLF. Given the low coal plant additions in the recent past, companies like NTPC with a high coal asset base and operational capability will benefit from the surge in demand in coming times.
- RE target and monetization: NTPC targets 60GW RE capacity by 2032. Of this, 40GW would come through competitive bid, 5GW through CPSUs and ~15GW for merchant/replacement of high cost coal with Solar during day/C&I/ hydrogen. Presently, ~11GW of RE capacity is under various stages - 3GW operational, ~5GW under construction ~3GW bids won. Management pointed that they are looking to monetize 10-20% of its Green portfolio.
- Valuation and outlook: We maintain our Mar-24 TP of Rs200/share, with BUY rating. We raise our FY23/FY24/FY25 EPS estimate by ~4% each. NTPC (~71GW installed capacity) has ~18GW of projects under construction - 11GW coal, ~5GWRE and ~2GW of Hydro majority of which will be commissioned over the next 3 years. We expect ~8% EPS CAGR in the medium term, with 12.2% RoE. Improvement in PLF, capacity addition and RE monetization are all positives.

Financial Snapshot (Standalone)

(Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	9,92,067	11,61,373	11,26,436	11,85,048	12,23,495
EBITDA	2,88,034	3,38,457	3,71,850	3,96,916	4,03,273
EBITDA Margin (%)	29.0	29.1	33.0	33.5	33.0
APAT	1,42,180	1,47,008	1,62,552	1,78,571	1,89,334
EPS (Rs)	14.7	15.2	16.8	18.4	19.5
EPS (% chg)	19.2	3.4	10.6	9.9	6.0
ROE (%)	12.2	11.9	12.3	12.6	12.5
P/E (x)	11.3	11.0	9.9	9.0	8.5
EV/EBITDA (x)	11.5	9.7	8.8	8.3	8.2
P/BV (x)	1.4	1.3	1.2	1.1	1.0

mkay Your success is our success

СМР	Target Price
Rs 166 as of (January 28, 2023)	Rs 200 (∎) 12 months
Rating	Upside
BUY (∎)	20.0 %

Change in Estimates

0								
EPS Chg FY2	3E/FY24	E (%)	4.3/4.1					
Target Price c	hange (%	»)	(0.0)					
Target Period	(Months)		12					
Previous Reco	2		BUY					
Emkay vs Co	nsensus							
EPS Estimates								
		FY23E	FY24E					
Emkay		16.8	18.4					
Consensus		16.9	19.0					
Mean Consen	sus TP (1	2M)	Rs 199					
Stock Details								
Bloomberg Co	ode		NTPC IN					
Face Value (F	₹s)		10					
Shares outsta	nding (mr	ר)	9,697					
52 Week H/L			183 / 124					
M Cap (Rs bn	/USD bn)	1,6	13 / 19.78					
Daily Avg Volu	ume (nos.	.) 1	17,52,270					
Daily Avg Tur	nover (US	SD mn)	24.6					
Shareholding	g Pattern	Dec '22						
Promoters			51.1%					
Flls			15.7%					
DIIs			30.5%					
Public and Otl	ners		2.7%					
Price Perforn	nance							
(%)	1M 3	M 61	M 12M					

Relative price trend

Absolute



1

(3)

11

23

Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

Abhineet Anand

abhineet.anand@emkayglobal.com +91 22 6624 2466

Chinmay Kabra

chinmay.kabra@emkayglobal.com +91 22 6624 2453

Source: Company, EmbauBesparcheam.emkay@whitemarquesolutions.com use and downloaded at 01/30/2023 01:55 PM

Enkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 1: Change in Estimates

Y/E, Mar (Rs mn)		FY23E			FY24E			FY25E	
T/E, Mar (KS IIII)	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
Revenue	11,18,112	11,26,436	0.7%	11,76,291	11,85,048	0.7%	12,14,454	12,23,495	0.7%
EBITDA	3,63,526	3,71,850	2.3%	3,88,159	3,96,916	2.3%	3,94,233	4,03,273	2.3%
EBITDAM (%)	32.5%	33.0%	50 bps	33.0%	33.5%	50 bps	32.5%	33.0%	50 bps
APAT	1,56,057	1,62,552	4.2%	1,71,713	1,78,571	4.0%	1,81,674	1,89,334	4.2%
EPS (Rs)	16.1	16.8	4.2%	17.7	18.4	4.0%	18.7	19.5	4.2%

Source: Company, Emkay Research

Exhibit 2: Quarterly Estimates

(Rs mn)	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	YoY (%)	QoQ (%)
Revenue	2,60,385	2,94,712	2,88,648	3,29,050	4,00,263	4,10,151	4,14,105	43.5	1.0
Expenditure	(1,85,996)	(2,17,480)	(1,98,029)	(2,27,845)	(3,02,814)	(3,18,803)	(2,81,713)	42.3	-11.6
as % of sales	-71.4%	-73.8%	-68.6%	-69.2%	-75.7%	-77.7%	-68.0%		
Fuel cost	(1,49,198)	(1,80,325)	(1,64,309)	(1,87,676)	(2,66,051)	(2,72,242)	(2,18,920)	33.2	-19.6
as % of sales	-57.3%	-61.2%	-56.9%	-57.0%	-66.5%	-66.4%	-52.9%		
Employee Cost	(12,578)	(13,598)	(13,265)	(13,709)	(13,295)	(12,074)	(14,978)	12.9	24.1
as % of sales	-4.8%	-4.6%	-4.6%	-4.2%	-3.3%	-2.9%	-3.6%		
Other expenditure	(24,220)	(23,557)	(20,455)	(26,460)	(23,469)	(34,488)	(47,815)	133.8	38.6
as % of sales	-9.3%	-8.0%	-7.1%	-8.0%	-5.9%	-8.4%	-11.5%		
EBITDA	74,389	77,232	90,619	1,01,206	97,449	91,348	1,32,392	46.1	44.9
Depreciation	(26,754)	(29,408)	(28,914)	(29,459)	(31,442)	(32,872)	(33,121)	14.6	0.8
EBIT	47,636	47,824	61,705	71,747	66,007	58,477	99,271	60.9	69.8
Other Income	7,637	8,347	9,723	12,250	6,994	7,958	7,383	-24.1	-7.2
Interest	(19,886)	(19,436)	(17,338)	(19,122)	(21,729)	(23,503)	(28,744)	65.8	22.3
Regulatory Deferral	7,874	4,597	(571)	1,398	(299)	8,121	(17,335)	2938.0	-313.5
PBT	43,261	41,331	53,520	66,273	50,973	51,053	60,575	13.2	18.7
Total Tax	11,805	9,764	12,200	10,054	13,804	17,741	15,812	29.6	-10.9
Reported PAT	31,456	31,567	41,320	56,219	37,170	33,312	44,763	8.3	34.4
Extra ordinary items	0	0	0	0	0	0	0		
Adjusted PAT	31,629	33,530	37,580	45,600	37,170	35,950	44,240	17.7	23.1
Adjusted EPS (Rs)	3.3	3.5	3.7	4.7	3.8	3.7	4.4	17.7	23.1
Margins (%)	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	(bps)	(bps)
EBITDA	28.6	26.2	31.4	30.8	24.3	22.3	32.0	58	970
EBIT	18.3	16.2	21.4	21.8	16.5	14.3	24.0	260	972
EBT	16.6	14.0	18.5	20.1	12.7	12.4	14.6	-391	218
APAT	12.1	11.4	13.0	13.9	9.3	8.8	10.7	-234	192
Effective Tax rate	27.3	23.6	22.8	15.2	27.1	34.8	26.1	331	-865

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/30/2023 01:55 PM

Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 3: SoTP-based valuation

	Value (Rs mn)	Multiple (x)	Comments	Value (Rs mn)	Per share (Rs)
Regulated equity	8,84,500	1.4	CoD in FY25	11,82,168	122
Investments in Subs and JVs	2,69,090	1	At book value	2,69,090	28
Investment in RE	1,50,000	1	12GW in medium term	1,50,000	15
Others (FGD/Coal mine)	76000/100000	1/1.4		2,16,000	22
Cash on books	45,000	1	At book value	45,000	5
Dividend over 12 months					8
Total					200
Source: Company, Emka	y Research				

Exhibit 4: Coal PLFs (%) have started to ramp up and can further rise

95 90 85 -	88.3 75	85 73.3	83.1	81.5	80.2	78.6	78.6	77.9	76.7				74.5
95 - 90 - 85 - 75 - 65 - 60 - 55 - 50 -	_		70.1	65.6	64.5	62.3	59.9	60.7	60.3	68.2 55.9	66 54.51	70.74 58.87	63.3
50 +	2010-11	2011-12	2012-13	2013-14	2014-15	% JTd 2015-16	2016-17	- All-Ind	2018-19 dia PLF	% 2019-20	2020-21	2021-22	YTDFY23

Source: Industry, Emkay Research




Exhibit 5: NTPC coal units had average PLF of ~90% during FY06-11, when the country was in deficit

Source: Industry, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/30/2023 01:55 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Key Financials (Standalone)

Income Statement

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	9,92,067	11,61,373	11,26,436	11,85,048	12,23,495
Expenditure	7,04,034	8,22,916	7,54,586	7,88,132	8,20,221
EBITDA	2,88,034	3,38,457	3,71,850	3,96,916	4,03,273
Depreciation	1,04,118	1,12,341	1,23,995	1,32,862	1,35,429
EBIT	1,83,916	2,26,116	2,47,854	2,64,054	2,67,845
Other Income	47,624	52,172	43,027	48,370	58,758
Interest expenses	74,590	73,509	87,691	89,210	89,935
РВТ	1,56,949	2,04,778	2,03,190	2,23,214	2,36,668
Тах	19,254	43,664	40,638	44,643	47,334
Extraordinary Items	4,485	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	1,37,695	1,61,114	1,62,552	1,78,571	1,89,334
Adjusted PAT	1,42,180	1,47,008	1,62,552	1,78,571	1,89,334

Balance Sheet

	EV04	EV.22	EVODE	EVO 4E	EVOEE
Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Equity share capital	96,967	96,967	96,967	96,967	96,967
Reserves & surplus	10,92,888	11,83,544	12,72,948	13,71,162	14,65,829
Net worth	11,89,855	12,80,511	13,69,914	14,68,128	15,62,795
Minority Interest	0	0	0	0	0
Loan Funds	17,36,162	17,06,471	17,53,816	17,84,203	17,98,690
Net deferred tax liability	91,610	1,00,063	1,00,063	1,00,063	1,00,063
Total Liabilities	30,17,627	30,87,044	32,23,794	33,52,394	34,61,548
Net block	16,44,489	18,00,658	17,72,660	18,17,132	17,33,036
Investment	2,86,256	2,98,811	3,28,811	3,68,811	4,18,811
Current Assets	7,46,639	7,58,528	8,29,690	8,53,957	8,71,154
Cash & bank balance	23,385	24,556	94,369	1,02,232	1,06,706
Other Current Assets	1,96,716	2,67,494	2,67,494	2,67,494	2,67,494
Current liabilities & Provision	4,14,143	4,57,924	4,37,006	4,39,810	4,42,425
Net current assets	3,32,497	3,00,605	3,92,684	4,14,147	4,28,730
Misc. exp	0	0	0	0	0
Total Assets	30,17,627	30,87,044	32,23,793	33,52,394	34,61,548

Cash Flow					
Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
PBT (Ex-Other income) (NI+Dep)	1,09,325	1,52,607	1,60,163	1,74,843	1,77,910
Other Non-Cash items	0	0	0	0	0
Chg in working cap	(63,732)	41,516	(22,266)	(13,600)	(10,109)
Operating Cashflow	1,75,310	4,06,881	3,59,113	3,94,183	4,01,342
Capital expenditure	(2,01,286)	(2,01,097)	(1,38,665)	(2,00,000)	(1,80,000)
Free Cash Flow	(25,976)	2,05,784	2,20,448	1,94,183	2,21,342
Investments	(22,247)	(12,554)	(30,000)	(40,000)	(50,000)
Other Investing Cash Flow	2,494	(47,374)	(54,167)	(59,511)	(59,511)
Investing Cashflow	(1,73,416)	(2,08,854)	(1,79,805)	(2,51,141)	(2,30,753)
Equity Capital Raised	(1,979)	0	0	0	0
Loans Taken / (Repaid)	1,30,281	(29,691)	47,346	30,386	14,487
Dividend paid (incl tax)	(55,311)	(69,331)	(73,148)	(80,357)	(94,667)
Other Financing Cash Flow	999	(24,325)	4,000	4,000	4,000
Financing Cashflow	(600)	(1,96,856)	(1,09,494)	(1,35,181)	(1,66,114)
Net chg in cash	1,294	1,171	69,814	7,862	4,475
Opening cash position	22,091	23,385	24,556	94,369	1,02,232
Closing cash position	23,385	24,556	94,370	1,02,231	1,06,707

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/30/2023 01:55 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Profitability (%)	FY21	FY22	FY23E	FY24E	FY25E
EBITDA Margin	29.0	29.1	33.0	33.5	33.0
EBIT Margin	18.5	19.5	22.0	22.3	21.9
Effective Tax Rate	12.3	21.3	20.0	20.0	20.0
Net Margin	13.9	13.9	14.4	15.1	15.5
ROCE	7.9	9.1	9.2	9.5	9.6
ROE	12.2	11.9	12.3	12.6	12.5
RolC	8.6	8.8	9.6	10.1	10.2
Per Share Data (Rs)	FY21	FY22	FY23E	FY24E	FY25E
EPS	14.7	15.2	16.8	18.4	19.5
CEPS	25.4	26.7	29.6	32.1	33.5
BVPS	122.7	132.1	141.3	151.4	161.2
DPS	5.7	5.7	7.5	8.3	9.8
Valuations (x)	FY21	FY22	FY23E	FY24E	FY25E
PER	11.3	11.0	9.9	9.0	8.5
P/CEPS	6.5	6.2	5.6	5.2	5.0
P/BV	1.4	1.3	1.2	1.1	1.0
EV / Sales	3.3	2.8	2.9	2.8	2.7
EV / EBITDA	11.5	9.7	8.8	8.3	8.2
Dividend Yield (%)	3.4	3.4	4.5	5.0	5.9
	5.4	3.4	4.5	5.0	5.9
Gearing Ratio (x)	FY21	FY22	FY23E	FY24E	FY25E
Net Debt/ Equity	1.4	1.3	1.2	1.1	1.1
Net Debt/EBIDTA	5.9	5.0	4.5	4.2	4.2
Working Cap Cycle (days)	113.7	86.8	96.7	96.1	96.1
Growth (%)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	1.5	17.1	(3.0)	5.2	3.2
EBITDA	6.3	17.5	9.9	6.7	1.6
EBIT	(0.4)	22.9	9.6	6.5	1.4
PAT	36.2	17.0	0.9	9.9	6.0
Quarterly (Rs mn)	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23
Revenue	2,88,648	3,29,050	4,00,263	4,10,151	4,14,105
EBITDA	90,619	1,01,206	97,449	91,348	1,32,392
EBITDA Margin (%)	31.4	30.8	24.3	22.3	32.0
PAT	36,249	45,600	37,170	35,950	42,440
FAI		4.7	3.8	3.7	4.4
	3.7				
EPS (Rs) Source: Company, Emkay Research	3.7				
EPS (Rs)	3.7 Dec-21	Mar-22	Jun-22	Sep-22	Dec-22
EPS (Rs) Source: Company, Emkay Research			Jun-22 51.1	Sep-22 51.1	
EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%)	Dec-21	Mar-22			51.1
EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%) Promoters	Dec-21 51.1	Mar-22 51.1	51.1	51.1	Dec-22 51.1 15.7 30.5

Source: Capitaline


This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/30/2023 01:55 PM Emkay Research is also available on www emkayglobal.com and Bloomberg EMKAY endows on the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 209 of Singapore.

RECOMMENDATION HISTORY (Rs/share)

Date	Closing Price	ТР	Period	Rating	Analyst
04-Jan-23	167	200	12m	Buy	Abhineet Anand
06-Dec-22	175	200	12m	Buy	Abhineet Anand
05-Nov-22	177	200	12m	Buy	Abhineet Anand
11-Sep-22	167	188	12m	Buy	Abhineet Anand
29-Aug-22	161	188	12m	Buy	Abhineet Anand
05-Jul-22	141	188	12m	Buy	Abhineet Anand
30-Jan-22	140	180	12m	Buy	Abhineet Anand
27-Dec-21	122	180	12m	Buy	Abhineet Anand
31-Oct-21	133	180	12m	Buy	Abhineet Anand
29-Sep-21	141	180	12m	Buy	Abhineet Anand
03-Aug-21	118	180	12m	Buy	Abhineet Anand
22-Jun-21	118	179	12m	Buy	Abhineet Anand

Source: Company, Emkay Research

RECOMMENDATION HISTORY (Rs/share)



Source: Bloomberg, Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/30/2023 01:55 PM

Emkay Research is also available on www emkayglobal com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Emkay Rating Distribution

Expected Return within the next 12-18 months.
Over 15%
Between -5% to 15%
Below -5%

Completed Date: 29 Jan 2023 20:13:05 (SGT) Dissemination Date: 29 Jan 2023 20:14:05 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors.

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/30/2023 01:55 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of January 29, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of January 29, 2023.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the January 29, 2023
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the January 29, 2023

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/30/2023 01:55 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

January 29, 2023 | 8

RESTRICTIONS ON D	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or
General	located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/30/2023 01:55 PM

Embray Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.